CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim
Saguil A, Lauters R
Take someone like Marcus, a 38-year-old recreational runner in San Jose
Additionally, patients on dual therapy would face doubled medication costs, doubled adherence burden, and no clinical evidence of superior outcomesmaking the risk-benefit calculation clearly unfavorable compared to optimizing a single agent
A small number of human studies have examined moringa's effect on metabolic markers
In the next year, we will have the study to show whether it makes sense to give finerenone to protect the kidney in people with type 1 diabetes and CKD. Other trials of note include Remodel T1D and SUGARNSALT, but neither is sponsored by a drug company